Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANX 005

Drug Profile

ANX 005

Alternative Names: ANX-005

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Annexon
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome; Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Guillain-Barre syndrome
  • Phase II Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Huntington's disease
  • No development reported Autoimmune disorders; Neurodegenerative disorders

Most Recent Events

  • 10 Jun 2024 Efficacy and adverse events data from a phase III trial in Guillain-Barre syndrome released by Annexon
  • 04 Jun 2024 Annexon Biosciences plans to submit BLA for Guillain-Barre syndrome in the first half of 2025
  • 12 Apr 2024 Annexon Biosciences plans a phase II/III trial in Amyotrophic lateral sclerosis (IV) (Annexon Biosciences pipeline, April 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top